World Investment Advisors raised its stake in Medtronic PLC (NYSE:MDT – Free Report) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,403 shares of the medical technology company’s stock after purchasing an additional 8,961 shares during the quarter. World Investment Advisors’ holdings in Medtronic were worth $16,081,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Artisan Partners Limited Partnership increased its holdings in shares of Medtronic by 2.6% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after acquiring an additional 31,314 shares during the last quarter. SageView Advisory Group LLC increased its holdings in shares of Medtronic by 164.8% during the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after acquiring an additional 15,062 shares during the last quarter. CSM Advisors LLC increased its holdings in shares of Medtronic by 13.2% during the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after acquiring an additional 33,167 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after acquiring an additional 54,898 shares during the last quarter. Finally, Applied Finance Capital Management LLC acquired a new position in shares of Medtronic during the 3rd quarter worth approximately $1,308,000. 82.06% of the stock is currently owned by institutional investors.
Trending Headlines about Medtronic
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Market reports highlight long-term demand growth in segments where Medtronic competes (anesthesia & respiratory devices; lung cancer surgery), supporting structural revenue tailwinds for MDT. Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035
- Positive Sentiment: Healthcare market analysis cites rising adoption of minimally invasive and robotic-assisted technologies — a growth area that includes Medtronic’s surgical portfolio. Global Lung Cancer Surgery Market | Rise at 5.9% CAGR
- Positive Sentiment: Several sell‑side firms (Citigroup, Evercore, Argus) cut price targets but maintained Buy/Outperform ratings, indicating confidence in MDT’s long‑term fundamentals despite near‑term modeling changes. Evercore Adjusts Medtronic Price Target to $108
- Neutral Sentiment: Headline market activity lifted NYSE-listed names, including MDT — broader market moves are contributing to today’s modest uptick rather than company‑specific news. Medtronic plc Climbs As NYSE Composite Shows Market Activity
- Neutral Sentiment: Comparative financial write‑ups (OMER vs MDT; MGNX vs MDT) provide investor context but contain no new MDT‑specific catalysts. Omeros and Medtronic Financial Review MacroGenics vs. Medtronic Financial Comparison
- Negative Sentiment: Stifel lowered its price target to $95 and reiterated a Hold, explicitly citing transaction‑related impacts from the MiniMed diabetes IPO / spin‑off as limiting near‑term upside; this is a direct headwind for sentiment. Stifel Cuts MDT Target to $95, Cites MiniMed IPO Effects
- Negative Sentiment: Analyst notes and coverage (TipRanks, Stifel commentary) emphasize that the MiniMed IPO/dilution and the diabetes spin‑off could cap near‑term stock appreciation, reinforcing cautious ratings. Medtronic: MiniMed IPO Dilution and Diabetes Spin-Off Limit Near-Term Upside
- Negative Sentiment: Competitive news: J&J launched an enhanced pulsed‑field ablation (PFA) platform in Europe — a potential competitive pressure in cardiac electrophysiology markets where Medtronic also competes. J&J launches enhanced PFA device in Europe
Analysts Set New Price Targets
Read Our Latest Stock Report on Medtronic
Medtronic Stock Performance
MDT opened at $86.40 on Wednesday. The business has a fifty day simple moving average of $93.90 and a 200 day simple moving average of $96.13. The company has a market capitalization of $110.92 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 2.24 and a beta of 0.75. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.
Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.46 EPS for the current year.
Medtronic Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.
Insider Buying and Selling at Medtronic
In other news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.
About Medtronic
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Recommended Stories
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
